Noemi Reguart/X
Apr 13, 2025, 17:50
Noemi Reguart: First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy in SCLC
Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“First global Phase 3 trial to show a substantial survival advantage over chemo in 2L SCLC!
Tarlatamab significantly improves OS after progression on platinum-based chemo.
More posts featuring SCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 17, 2025, 16:14
Jun 17, 2025, 16:00
Jun 17, 2025, 15:44
Jun 17, 2025, 15:30
Jun 17, 2025, 14:35
Jun 17, 2025, 14:28